Splenectomy as a Treatment for Patient With Relapsed Haemophagocytic Lymphohistiocytosis of Unknown Etiology

Capital Medical University

Status and phase: Unknown; Phase 3; Phase 2

Conditions: Hemophagocytic Lymphohistiocytosis

Treatments: Procedure: splenectomy

Study type: Interventional

Funder types: Other

Identifiers

NCT02862054

Splenectomy-HLH

Details and patient eligibility

About

To evaluate the clinical value of splenectomy as a treatment for relapsed haemophagocytic lymphohistiocytosis (HLH) in patient with unknown etiology.

Enrollment: 30 estimated patients

Sex: All

Ages: 14 to 60 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Patients were older than 14 years of age
2. Diagnosed as Hemophagocytic Lymphohistiocytosis (HLH) according to HLH-2004.
3. patients were excluded with infection, rheumatic and immunologic diseases, malignant tumors (especially lymphoma), and primary HLH.
4. Informed consent

Exclusion criteria

1. Pregnancy or lactating Women
2. Active bleeding of the internal organs
3. Uncontrollable infection
4. Contraindication of splenectomy
5. Participate in other clinical research at the same time

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

30 participants in 1 patient group

Splenectomy

Experimental group

Description:

Splenectomy as a treatment for patient with relapsed haemophagocytic lymphohistiocytosis of unknown etiology

Treatment:

Procedure: splenectomy